Medicare Part B Premiums Tick Up, But Drug Subsidy Cut Lurks for 2027

For 2027, Medicare Part B premiums are projected to increase by 3.5%, reaching an estimated $209.50 per month

"For 2027, the premium is currently projected to rise 3.5% to $209.50, up $6.60 from $202.90 in 2026."

. This might seem like a manageable jump compared to previous years, but the real sting for many beneficiaries could come from the simultaneous expiration of a federal subsidy for Medicare Part D prescription drug plans

"Now, Trump wants to eliminate Medicare Part D subsidies that help millions of older and disabled Americans afford their prescriptions. It's unconscionable, and Congressional Democrats will keep fighting to ensure every American has access to quality, affordable healthcare."

. While official announcements from the Centers for Medicare & Medicaid Services (CMS) focus on strengthening accountability and sustainability in Medicare Advantage and Part D programs [c1, c2], this subsidy's end is often a secondary detail. For individuals relying on this assistance, the loss of the subsidy could significantly inflate out-of-pocket spending on medications, a consequence that overshadows the smaller Part B premium hike. This dual policy shift demands a closer look beyond the headline figures, as it represents a tangible increase in healthcare expenses for a significant portion of seniors and disabled Americans.

The annual drumbeat of Medicare premium increases is a predictable rhythm in the lives of seniors. For 2027, the melody is a relatively gentle one: a 3.5% rise in the standard Part B premium, pushing it to an estimated $209.50 from $202.90

"For 2027, the premium is currently projected to rise 3.5% to $209.50, up $6.60 from $202.90 in 2026."

. This figure, while notable, is considerably less jarring than some prior years' jumps. The Centers for Medicare & Medicaid Services (CMS) has framed its finalized policies for Medicare Advantage and Part D as moves to enhance program stability and accountability [c1, c2]. However, this focus on the Part B premium often distracts from more impactful changes lurking in the policy footnotes.

What's often lost in the conversation about Part B premiums is the impending expiration of a federal subsidy that helps millions afford their Part D prescription drugs. This subsidy's end, a detail that has drawn sharp criticism from lawmakers like Rep. Jim Himes

"Now, Trump wants to eliminate Medicare Part D subsidies that help millions of older and disabled Americans afford their prescriptions. It's unconscionable, and Congressional Democrats will keep fighting to ensure every American has access to quality, affordable healthcare."

, could lead to a significant increase in out-of-pocket drug costs for many beneficiaries. While CMS's rate announcements for Medicare Advantage and Part D plans focus on payment accuracy and competition

Today, CMS released the Calendar Year 2027 Medicare Advantage (MA) and Part D Rate Announcement to improve payment accuracy and competition across both programs. The finalized policies also advance CMS’ vision of a sustainable and stable MA program that offers high-quality…

— CMSGov link

, the removal of this financial cushion for drug costs is a critical, and often overlooked, consequence. It's a policy shift that directly impacts the affordability of essential medications, a concern that goes far beyond the monthly Part B bill.

The financial markets have already begun to digest the CMS's finalized rules for Medicare Advantage and Part D, with some health insurance stocks showing positive movement following news of a 2.48% average increase in Medicare Advantage payments [c3, c4]. Companies like UnitedHealth, Humana, and Oscar Health are reportedly trading higher on this news

$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh

— Wall St Engine link

. This suggests that, from an industry perspective, the regulatory landscape for 2027 is viewed as favorable, or at least less punitive than feared. However, this market reaction stands in contrast to the potential financial strain on beneficiaries, particularly those whose prescription drug costs are set to rise due to the subsidy's end. The industry's gain could well be the beneficiary's pain.